Compare Digital Realty Trust, Inc. (DLR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Digital Realty Trust, Inc. vs Summit Therapeutics Inc — how do they compare? Digital Realty Trust, Inc. trades at $177.52 (market cap $65.32B), while Summit Therapeutics Inc trades at $17.39 (market cap $13.71B). The key difference: Digital Realty Trust, Inc. is far larger — about 4.8× Summit Therapeutics Inc's market cap, and Digital Realty Trust, Inc. pays a 2.77% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Digital Realty Trust, Inc. for 94 Days and Summit Therapeutics Inc for 16 Days on average.
| DLR | SMMT | |
|---|---|---|
Market Cap | $65.32B | $13.71B |
Volume | 2,563,950 | 6,173,057 |
Sector | Real Estate | Health |
52-Week High | $203.91 | $26.38 |
52-Week Low | $147.93 | $12.43 |
Typical Hold Time | 94 Days | 16 Days |
Enterprise Value | $84.03B | $13.04B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLR trades at $180.47, down 2.26% today, with a bearish technical signal. The stock shows strong fundamentals: revenue grew to $6.11B in 2025, net income margin improved to 21.4%, and Q2 2026 EPS beat expectations. Analysts are overwhelmingly bullish with a $222.35 consensus target. Recent news highlights AI infrastructure expansion, including a partnership with Blackfuel and a new cable landing station in Los Angeles, driving positive sentiment.
Outlook is positive due to robust AI-driven demand and record leasing activity, but risks include high valuation (P/E 88.03) and significant capital expenditures. Net cash flow turned negative in 2025, and debt levels remain elevated. The stock offers growth potential from the AI boom, yet investors should weigh execution risks and macroeconomic sensitivity.
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% with strong technical momentum and bullish analyst sentiment. The stock shows negative profitability metrics but benefits from AstraZeneca's $2 billion strategic investment and clinical collaborations. Recent news highlights positive clinical trial results for ivonescimab, driving investor optimism despite current financial losses.
The outlook remains speculative with significant upside potential based on analyst consensus targets averaging $29.33, though high valuation multiples and negative cash flows present substantial risk. Success of clinical trials and partnership execution will determine long-term value creation for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Digital Realty Trust, Inc.
Digital Realty owns and operates nearly 300 data centers worldwide. It has more than 35 million rentable square feet across five continents. Digital's offerings range from retail co-location, where an enterprise may rent a single cabinet and rely on Digital to provide all the accommodations, to cold shells, where hyperscale cloud service providers can simply rent much, or all, of a barren, power-connected building. In recent years, Digital Realty has de-emphasized cold shells and now primarily provides higher-level service to tenants, which outsource their related IT needs to Digital. Digital Realty has also moved more into the co-location business, increasingly serving enterprises and facilitating network connections. Digital Realty operates as a real estate investment trust.
Read more on DLR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
